Neuromyelitis optica (NMO) antibody positivity in patients with transverse myelitis and no visual manifestations

Seminars in Ophthalmology

Volumn 23, Issue 3, 2008, Pages 191-200

  Hamnik, Sheri E ^a   Hacein Bey, Lotfi ^a   Biller, José ^a   Gruener, Gregory ^a   Jay, Walter ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Aquaporin 4 IgG protein; Devic's disease; Neuromyelitis optica (NMO)

Indexed keywords

ALBUMIN; ANTINUCLEAR ANTIBODY; AQUAPORIN 4; AZATHIOPRINE; BACLOFEN; CEFALEXIN; GABAPENTIN; IBUPROFEN; IMMUNOGLOBULIN G; INTERLEUKIN 6; METHYLPREDNISOLONE; MYELIN BASIC PROTEIN; OLIGOCLONAL BAND; PREDNISOLONE; THYROID PEROXIDASE ANTIBODY;

ADOLESCENT; ADULT; AFRICAN AMERICAN; AGED; ALBUMIN BLOOD LEVEL; ALLODYNIA; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DRUG WITHDRAWAL; EPIGASTRIC DISCOMFORT; FEMALE; HISPANIC; HUMAN; IMMUNOASSAY; IMMUNOGLOBULIN BLOOD LEVEL; LEG PAIN; LIFESPAN; LONG TERM CARE; MALE; MUSCLE CRAMP; MYELITIS; MYELOOPTIC NEUROPATHY; OPTIC NERVE LESION; PLEOCYTOSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RASH; SCHOOL CHILD; SEROLOGY; SPASTICITY;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED, 80 AND OVER; ANTIBODIES, ANTINUCLEAR; AQUAPORIN 4; AUTOANTIBODIES; CHILD; FEMALE; GLUCOCORTICOIDS; HUMANS; INFUSIONS, INTRAVENOUS; IODIDE PEROXIDASE; MAGNETIC RESONANCE IMAGING; MALE; METHYLPREDNISOLONE; MIDDLE AGED; MYELITIS, TRANSVERSE; NEUROMYELITIS OPTICA; OPTIC NEURITIS; PREDNISONE;

EID: 42449090743     PISSN: 08820538     EISSN: 17445205     Source Type: Journal    
DOI: 10.1080/08820530802049921     Document Type: Article

References (53)

1. Allbutt T. On the ophthalmoscopic signs of spinal disease. Lancet 1870;1:76-79.
2. Devic E. Myelite subaiguë compliquée de névrite optique. Bull Med. 1894; 8:1033-34.
3. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006; 66:1485-89.
4. Roemer SF, Parisi JE, Lennon VA, et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain. 2007; 130:1194-1205.
5. Pittock S, Weinshenker B, Lucchineli C, Wingerchuck D, Corbey J, Lennon V. Neuromyelitis Optica Brain Lesions Localized at Sites of High Aquaporin 4 Expression. Arch Neurol. 2006; 63:964-68.
6. Wingerchuck DM. Neuromyelitis optica. The International MS Journal 2006; 13:42-50. PMID 16635421.
7. O'Riordan J, Gallagher HL, Thompson AJ, et al. Clinical, CSF, and MRI findings in Devic's neuromyelitis optica. Neurol, Neurosurg and Psychiatry. 1996; 60:382-7.
8. Misu T, Fujihara K, Kakita A, Konno H, Nakamura M, Watanabe S, et al. Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain. 2007; 130:1224-34.
9. Wingerchuck DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999; 53: 1107-14.
10. Matiello M, Jacob A, Wingerchuck DM, Weinshenker BG. Neuromyelitis optica. Current Opinions in Neurology. 2007; 20(3): 255-60.
11. Weinshenker BG, Pittock S, Kryzer T, Nakashima I, Yasutoltoyama, Lennon V. The Asian opticospinal form of MS is the same entity as neuromyelitis optica in Caucasions: Insights from a novel serum marker Neurology. 2004; 62 (7.suppl 5): A480.
12. Cabre P, Heinzlef O, Merle H, Buisson GG, Bera O, Bellance R, et al. MS and neuromyelitis optica in Martinique (French West Indies). Neurology. 2001; 56(4):507-514.
13. Yamakawa, K, Karoda, K, Fujinara, S et al. Familial neuromyelitis optica (Devic's syndrome) with late onset in Japan. Neurology 2000, 55:318-320.
14. McAlpine D. Familial neuromyelitis optica: its occurrence in identical twins. Brain 1938; 61:430-48.
15. Hudson G, Mowbray C, Elson J, Jacob A, Boddild M, Torroni A, Chinnery P. Does mitochondrial DNA predispose to neuromyelitis optica (Devic's disease)? Brain. August 2007, E1-E5.
16. Keegan M, Weinshenker B. Familial Devic's disease. Can J Neurol Sci. 2000; 27:S57-58.
17. Celebisoy N, Akyurekli O, Copur A. Devic's neuromyelitis optica: a case with mitochondrial DNA mutations. Eur Neurol. 2006; 55:93-5.
18. Kalman B, Mandler RN. Studies of mitochondrial DNA in Devic's disease revealed no pathogenic mutations but polymorphisms also found in association with multiple sclerosis. Ann Neurol. 2002; 51661-2.
19. Carelli V, Ross-Cisneros FN, Sadun AA. Mitochondrial dysfunction as a cause of optic neuropathies. Prog Retin Eye Res. 2004; 23: 53-89.
20. Herrera BM, Ebera OC. Progress in deciphering the genetics of multiple sclerosis. Current Opinions in Neurol 2003; 16:253-258.
21. Ghezzi A, Baldini S, Zaffaroni M, Leoni G, Koudriavtseva T, Casini AR et al. Devic's neuromyelitis optica and mitochondrial DNA mutation: a case report. Neurol Sci. 2004; Suppl. 4:S380-S382.
22. Hensuk AE, Sawcer SJ, Feckes R, et al. HLA DR 15 is associated with female sex and younger age at diagnosis in MS. J Neurol Neurosurg, Psych 2002; 72:184-87.
23. Weinshenker BG. Neuromyelitis optica: what it is and what it might be. Lancet. 2003; 361 (9361): 889-890.
24. Jacob A, Boggild M. Neuromyelitis Optica: A 10 year experience from a regional center. J Neurol Neurosurg Psych. 2003; 75:803.
25. Wingerchuck DM. Neuromyelitis optica: current concepts. Front Biosci. 2004; 9:834-40.
26. Pittock S, Lennon V, Krecke K, Wingerchuck D, Lucchinetti C, Weinshenker B. Brain Abnormalities in patients with neuromyelitis optica. Arch Neurol. 2006; 63:390-96.
27. Mandler RN, Davis LE, Jeffery DR, Kornfeld M. Devic's neuromyelitis optica: a clinicopathological study of 8 patients. Ann of Neurol 1993; 34:162-8.
28. Wingerchuck DM. Evidence for humoral autoimmunity in neuromyelitis optica. Neurol Res. 2006; 28:348-53.
29. Dalakas MC. B-cells in the pathophysiology of autoimmune neurological disorders: a credible therapeutic target. Pharmacol Ther. 2006; April 24; 112(1):57-70.
30. Weinshenker BG, O'Brien PC, Petterson TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol.1999; 46:878-86.
31. MacReady N. Autoantibody Discovery Sheds Light on NMO, MS Differentiation. Applied Neurology. September 2006; 8-14.
32. de Seze J. Neuromyelitis optica. Arch Neurol. 2003; 60(9):1336-1338.
33. Jacob A, Nicholas R, Das K, Boggild M. Neurolmyelitis optica in the UK; clinical, epidemiological, radiological and treatment profile. Proceedings of the Association of British Neurologists. Queens University of Belfast, Ireland. J Neurol Neurosurg Psych. 2005; 76:1313-26.
34. Bergamaschi R, Tonietti S, Franciotta D, Candeloro E, Tavazzi E, Piccolo G, et al. Oligoclonal bands in Devic's neuromyelitis optica and multiple sclerosis: differences in repeated cerebrospinal fluid examinations. Mult Scler. 2004; 10 (1):2-4.
35. Narikawa K, Misu T, Fujihara K, Nakashima I, Sato S, Itoyama Y. CSF chemokine levels in relapsing neuromyelitis optica and multiple sclerosis. J Neuroimmunol. 2004; 149(1-2):182-86.
36. Lennon VA, Wingerchuck DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004; 364:2106-112.
37. Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005; 202:473-77.
38. Lu M, Lee MD, Smith BL, Jung JS, Agre P, Verdijk MA, et al. The human AQP4 gene: definition of the locus encoding two water channel polypeptides in brain. Proc Natl Acad Sci USA. 1996. 93:10908-12.
39. Takahashi T, Fujihara K, Nakashima I, Misu T, Miyazawa I, Nakamura M. et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain. 2007. 130:1235-43.
40. Kelly J. New biomarker differentiates neuromyelitis optica from MS. Neurol. Rev. 2005;13.
41. Jarius S, Friedemann P, Franciolta D, Orhan A, Hohlfeld R, Zipp F, Vincent A. Revised Diagnostic Criteria for neuromyelitis optica-incorporation of NMO-IgG status. Nat Clin Pract Neurol 2007; 3:132-33
42. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology 2003; 60(5):848-53.
43. Lennon VA, Weinshenker BG. Identification of a marker autoantibody of Neuromyelitis Optica. Neurology 2003; 60(5 suppl 1):A519.
44. Jacob A NR, Das K, Boggild M. Exploring the relationship between relapsing myelitis, neuromyelitis optica and multiple sclerosis. Journal of Neurology Neurosurg and Psych. 2004; 75(8):1225.
45. Luchinetti CF, Mandler RN, McGavern D, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain. 2002; 125:1450-61.
46. Kister I, Gulati S, Boz C, et al. Neurolmyelitis optica in patients with myasthenia gravis who underwent thymectomy. Arch Neurol. 2006; 63:851-56.
47. Keegan M, Pineda AA, McClelland RI, et al. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology. 2002; 58:143-46.
48. Mandler, RN, Waseem A, Dencoff J. Devic's neuromyelitis optica: A prospective study of seven patients treated with prednisone and azathioprine. Neurology. 1998; 51(4):1219-20.
49. Bennetto L, Totham A, Healy P, et al. Plasma exchange in episodes of severe inflammatory demyelination of the central nervous system. A report of six cases. J Neurol. 2004; 251:1515-21.
50. Bakker J, Metz L. Devic's neuromyelitis optica treated with intravenous gamma globulin (IVIG). Can J Neurol Sci 2004; 31(2):265-67.
51. Cree B, Lamb S, Morgan K, et al. An open-label study of the effects of rituximab in neuromyelitis optica. Neurology. 2005; 64:1270-72.
52. Cree BA, Goodwin DS, Hauser SI. Neuromyelitis optica. Semin Neurol. 2002; 22:105-122.
53. Reynier P, Penisson-Besnier I, Moreau C, Savagner F, Vielle B, Emile J. et al. mtDNA haplogroup J: a contributing factor of optic neuritis. Eur J Hum Genetics. 1999; 7:404-6.